Evidence map›Paper›PMID 31745177›Full record

ArticleScientific reports2019

Enhancing Colorectal Cancer Radiation Therapy Efficacy using Silver Nanoprisms Decorated with Graphene as Radiosensitizers.

Khaled Habiba, Kathryn Aziz, Keith Sanders, Carlene Michelle Santiago, Lakshmi Shree Kulumani Mahadevan, Vladimir Makarov, Brad R Weiner, Gerardo Morell, Sunil Krishnan

Abstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Application of nano-radiosensitizers in combination cancer therapy.Bioengineering & translational medicine · 2023
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Cancer Therapy by Silver Nanoparticles: Fiction or Reality?International journal of molecular sciences · 2022
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Khaled HabibaDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. khabiba@gmail.com.
Kathryn AzizDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Keith SandersDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Carlene Michelle SantiagoDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Lakshmi Shree Kulumani MahadevanDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Vladimir MakarovMolecular Sciences Research Center, University of Puerto Rico, San Juan, Puerto Rico, 00926-2614, USA.ORCID http://orcid.org/0000-0003-1813-1837
Brad R WeinerMolecular Sciences Research Center, University of Puerto Rico, San Juan, Puerto Rico, 00926-2614, USA.
Gerardo MorellMolecular Sciences Research Center, University of Puerto Rico, San Juan, Puerto Rico, 00926-2614, USA.
Sunil KrishnanDepartment of Radiation Oncology, Mayo Clinic Florida, Jacksonville, FL, 32224, USA. krishnan.sunil@mayo.edu.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
UPR/MDACC Partnership for Excellence in Cancer Research(Parent Grant U54 CA096297)U54CA096297 · NCI · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI Ilka C Rios · 2002 to 2026
$36.9M
UPR/MDACC Partnership for Excellence in Cancer Research (Luis Segarra supplement)U54CA096300 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Larkin Strong · 2002 to 2026
$23.8M
NCI NIH HHS P30 CA016672NCI NIH HHS U54 CA096297NCI NIH HHS U54 CA096300
6 · The paper itself

Abstract

Metal nanoparticles have significant interaction cross-sections with electromagnetic waves due to their large surface area-to-volume ratio, which can be exploited in cancer radiotherapy to locally enhance the radiation dose deposition in tumors. We developed a new type of silver nanoparticle composite, PEGylated graphene quantum dot (GQD)-decorated Silver Nanoprisms (pGAgNPs), that show excellent in vitro intracellular uptake and radiosensitization in radiation-sensitive HCT116 and relatively radiation-resistant HT29 colorectal cancer cells. Furthermore, following biodistribution analysis of intravenously injected nanoparticles in nude mice bearing HCT116 tumors radiosensitization was evaluated. Treatment with nanoparticles and a single radiation dose of 10 Gy significantly reduces the growth of colorectal tumors and increases the survival time as compared to treatment with radiation only. Our findings suggest that these novel nanoparticles offer a promising paradigm for enhancing colorectal cancer radiation therapy efficacy.

Indexed as

AnimalsApoptosisCell ProliferationColorectal NeoplasmsGamma RaysGraphiteHumansMaleMetal NanoparticlesMiceQuantum DotsRadiation-Sensitizing AgentsSilverTumor Cells, CulturedXenograft Model Antitumor AssaysGraphiteRadiation-Sensitizing AgentsSilver

Identifiers

PMID31745177
PMCPMC6864075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.